PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

PLoS One · 2011 · PMC3146490 · PMID 21829508

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

16/283 [6%] in wt KRAS ; p = 0.001), whereas the association between exon 20 PIK3CA and KRAS mutations did not reach statistical significance (7/57 [12%] in KRAS mutant vs. 15/282 [5%] in wt KRAS ; p = 0.07).

also in 111,027 other papers

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

In colorectal cancer, exon 9 PIK3CA mutations showed a trend towards increased frequency in patients with KRAS mutations (9/45; 20%) compared to patients with wt KRAS (3/46; 6%) (p = 0.07), whereas the frequency of exon 20 PIK3CA mutations did not significantly differ (4/40 [10%] in KRAS mutant vs. 2/45 [4%] in wt KRAS ; p = 0.4).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.